Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (11261)	8/17/1999 3:43:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Berlin seems to indicate 5.5 ish area. I found this press release from 1997 of note. Notice the wording like "preliminary" and "believe". etc............Sound familiar?. All IMO etc..... > BERKELEY, CA -- February 27, 1997 -- XOMA Corporation (Nasdaq: XOMA) announced positive results from a 400-patient Phase II clinical trial in patients suffering hemorrhagic trauma (acute loss of blood). Preliminary analysis of the data showed a positive overall benefit in patients receiving Neuprex(tm) versus placebo for the primary endpoint in this study, defined as a reduced incidence of serious organ dysfunction, infections, and death. Product safety was also confirmed across the entire patient population. Based on its preliminary review, XOMA believes the results support advancing Neuprex(tm) to a Phase III trauma study, which will be the second pivotal study for the product. The company is completing a comprehensive analysis of data from this trial which, with additional data from an ongoing trauma pharmacokinetics study, will be used in the pivotal trial design

To: Bluegreen who wrote (11261)	8/17/1999 12:05:00 PM
From: RXGOLF	Respond to of 17367

<<Once again Xoma thinks it would be a stupid move to grandstand their data at this point in time. If I had it my way and seeing how the FDA operates I wouldn't of even told you what Castello did today. My money is riding on Xoma getting approval not grandstanding data at this juncture. >> Grandstanding data?? I'm sorry, but IMO the simple stating of the data is not grandstanding. The release of data would be what I would expect if data was strong. I'm sure Castello did yesterday what he thought was best for XOMA. My view of the events was just different from what you saw. Good Luck, Greg